News
AMN Healthcare Announces Preliminary Fourth Quarter 2020 Revenue; To Present at J.P. Morgan Healthcare Conference
In connection with the Company’s participation at the 39th Annual J.P. Morgan Healthcare Conference on January 12, 2021, AMN Healthcare Services Inc. (NYSE: AMN) is providing preliminary unaudited
Charles River Laboratories to Present at J.P. Morgan Healthcare Conference
Charles River Laboratories International, Inc. (NYSE: CRL) announced today that it will virtually present at the 39th Annual J.P. Morgan Healthcare Conference on Tuesday, January 12th, at 10:00
Novocure Announces Fourth Quarter and Full Year 2020 Preliminary Net Revenues and Provides Company Update
Novocure (NASDAQ: NVCR) today reported operating statistics and preliminary, unaudited net revenues and cash balances for the fourth quarter and full year 2020. Novocure plans to discuss these
QIAGEN benennt neues Aufsichtsratsmitglied
QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) gab heute die Berufung von Dr. Toralf Haag in den Aufsichtsrat mit sofortiger Wirkung bekannt. Dr. Haag wird gleichzeitig Mitglied des
QIAGEN Announces Appointment of New Supervisory Board Member
QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) announced today that Dr. Toralf Haag has been appointed a member of the Supervisory Board with immediate effect. He will also become a member of
Premier, Inc. to Report Fiscal 2021 Second-Quarter Results and Host Conference Call on February 2, 2021
Premier, Inc. (NASDAQ: PINC) today announced that it will release financial results for its fiscal 2021 second quarter on Tuesday, February 2, 2021, at approximately 6:30 a.m. ET. The company will
ICON plc to Present at the 39th Annual JP Morgan Healthcare Conference
ICON plc, (NASDAQ: ICLR) a global provider of outsourced drug and device development and commercialisation services to pharmaceutical, biotechnology, medical device and government and public health
Xencor and MD Anderson Enter Strategic Collaboration to Develop Novel T Cell-Engaging Bispecific Antibodies for Potential Treatment of Patients with Cancer
Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of cancer and autoimmune diseases, and The University of Texas
Premier Inc. to Participate in the 39th Annual J.P. Morgan Virtual Healthcare Conference on January 12, 2021
Premier Inc. (NASDAQ: PINC), a leading healthcare improvement company, announced today that members of its management team are scheduled to participate in a presentation and fireside chat at the 39
Charles River Laboratories Acquires Distributed Bio
Charles River Laboratories International, Inc. (NYSE: CRL) announced today that it acquired of Distributed Bio, Inc. on December 31, 2020. The acquisition marks the culmination of an exclusive
Acadia Healthcare Announces Definitive Agreement to Sell U.K. Operations
Acadia Healthcare Company, Inc. (NASDAQ: ACHC) (“Acadia” or the “Company”) today announced that it has entered into a definitive agreement to sell its U.K. operations to Waterland Private Equity
Novocure to Participate in the 39th Annual J.P. Morgan Virtual Healthcare Conference
Novocure (NASDAQ: NVCR) will participate virtually in the 39th Annual J.P. Morgan Healthcare Conference on January 11 through January 14, 2021. William Doyle, Novocure’s Executive Chairman, will
VFMCRP and ChemoCentryx Provide Topline Results From ACCOLADE Trial of Avacopan in C3 Glomerulopathy Including Improved Estimated Glomerular Filtration Rate (eGFR)
Regulatory News:
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201221005694/en/
Vifor Fresenius Medical Care Renal Pharma (VFMCRP)
Health Resource Services (HRS) Moves to Premier Inc. for Superior National Contract Portfolio and Comprehensive, Cross-Continuum Spend Management Services
Health Resource Services (HRS), a national, provider-owned group purchasing organization (GPO) founded by Virginia Mason Health System, today announced that they will partner with Premier Inc.
QIAGEN unterstreicht innovatives Engagement für Nachhaltigkeit mit einem EUR 400 Mio. syndiziertem Kredit mit Nachhaltigkeitsbezug
QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard QIA) gab heute den erfolgreichen Abschluss eines syndizierten revolvierenden Kredits über EUR 400 Mio. bekannt, deren Zinssatz an die Umwelt-
QIAGEN Underlines and Innovates Its Commitment to Sustainability With a EUR 400mn Sustainability-linked Credit Facility
QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard QIA) announced today that it has successfully concluded a syndicated revolving credit facility for EUR 400mn with an interest rate linked to the
AMN Healthcare Named as One of America’s Most Responsible Companies for 2021
For its dedication to addressing social issues and supporting people and communities locally, nationally and globally, AMN Healthcare (NYSE: AMN) has been named one of the country’s most
Novocure meldet nationale Kostenübernahme in der Schweiz für Optune® in Kombination mit Temozolomid zur Behandlung von neu diagnostiziertem Glioblastom
Novocure (NASDAQ:NVCR) gab heute bekannt, dass das Schweizerische Bundesamt für Gesundheit (BAG) Optune in Kombination mit Temozolomid mit Wirkung vom 1. April 2021 in die Mittel- und
Novocure Announces National Reimbursement in Switzerland for Optune® in Combination With Temozolomide for the Treatment of Newly Diagnosed Glioblastoma
Novocure (NASDAQ:NVCR) announced today that the Swiss Federal Office of Public Health (BAG) has added Optune in combination with temozolomide to the List of Remedies and Equipment (MiGeL) for the
QIAGEN N.V. Announces Conversion Price of New Net Share Settled Convertible Bonds and Price to Non-US Holders to Sell Outstanding Convertible Notes Due 2021
QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) ("QIAGEN" or the "Company") announces the successful pricing of the following series of transactions:
- The issue of new senior, unsecured
First Patient Enrolled in Novocure’s Global Phase 3 TRIDENT Trial of Optune® Concurrent with Radiation Therapy in Newly Diagnosed Glioblastoma
Novocure (NASDAQ: NVCR) today announced the first patient has been enrolled in its global phase 3 TRIDENT trial, a randomized study in newly diagnosed glioblastoma (GBM) testing the potential
Acadia Healthcare Forms Joint Venture with Henry Ford Health System to Build Modern Behavioral Health Facility to Serve Detroit Area Communities
Acadia Healthcare Company, Inc. (NASDAQ: ACHC) today announced that it has formed a joint venture with Henry Ford Health System, one of Michigan’s premier, academic and integrated health systems
Charles River Delivers Industry-First Deciphex Patholytix Digital Pathology Peer Review for GLP Studies
Charles River Laboratories International, Inc. (NYSE: CRL) today announced that it is the first company to offer clients Good Laboratory Practices (GLP) validated digital peer review using Deciphex
QIAGEN Increases Outlook for 2020 and 2021
QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) announced today that it has raised its full-year 2020 outlook for growth of net sales and adjusted earnings per share (EPS) and is looking forward
QIAGEN hebt den Ausblick für 2020 und 2021 an
QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) gab heute bekannt, dass es den Ausblick für das Wachstum des Konzernumsatzes und den bereinigten Gewinn je Aktie (EPS) für das Gesamtjahr 2020